Viatris Inc. (VTRS) Next Earnings Date & Expected ±5.4% Move

Per the Roarable RQD rating, VTRS scores 57 out of 100, a D+ grade with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

• Fundamental Cash Engine: 7 / 20. Per the RQD rating, ROIC is -8.1% and FCF yield is 8.78%. This is the weakest pillar in relative terms. A positive FCF yield indicates cash generation relative to market value, but negative ROIC indicates the company is not currently earning a return on invested capital.
• Whale 13F Flow: 18 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. It is the strongest pillar and suggests institutional interest that runs counter to the weak fundamentals.
• Insider Conviction: 12 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The score is moderate.
• Macro Regime Fit: 12 / 20. Per the RQD rating, beta is 1.15 and sector sensitivity is noted. Beta above 1.0 implies the stock has historically moved somewhat more than the broader market.
• Forensic Balance Sheet: 8 / 20. Per the RQD rating, Altman Z is 0.81, Piotroski F is 6/9, and Debt/Equity is 0.85. The Altman Z reading sits in the range the rating frames as distressed, which is the primary driver of the low forensic score.

For a prospective investor, the composite picture is mixed: strong institutional positioning is offset by weak operating returns and a stressed balance-sheet signal. The rating's verdict is that fundamentals currently outweigh the positioning signals. The forward P/E of 33 (per Market Data) implies the market is pricing meaningful earnings recovery, which is a valuation tradeoff the RQD framework treats as a risk rather than a support.

Per the SEC financials, revenue declined from $15388.4M (FY 2023) to $14250.4M (FY 2025), and operating income moved from $766.2M to $-2663.1M over the same span. Per the Market Data section, gross margin is 35.2%, operating margin is -18.7%, and net margin is -14.6%. Per the Roarable RQD rating, ROIC is -8.1%, the Altman Z-Score is 0.81, the Piotroski F-Score is 6/9, and Debt/Equity is 0.85. Reported net income is $0.0M in each period shown, and EPS is listed as N/A in the financial table.

Per the recent news section, the dominant catalyst is Viatris's agreement to acquire Pacira BioSciences, framed in headlines as advancing its innovative medicines strategy and non-opioid pain therapies. Multiple outlets (Yahoo Finance, Seeking Alpha, Benzinga) cover the deal, and one headline references Pacira's stock rising. A GuruFocus item cites a share price surge of 4.5% and a GF Score of 63, flagged as a catalyst. Source data does not provide deal terms, price, financing, or closing timing.

Risk watch items: the source data does not quantify deal size or how it would be funded relative to the existing $12480.6M in FY 2025 debt. The Yahoo Finance headline references "fair value," indicating valuation debate. Per the Butterfly graph, there are no supply-chain links or proprietary signals in the source data.

• What are the terms, price, and financing structure of the Pacira BioSciences acquisition, and how would they affect the FY 2025 debt load of $12480.6M?
• What drove the swing in operating income from $766.2M (FY 2023) to $-2663.1M (FY 2025), and is it recurring or one-time?
• Why is net income reported as $0.0M across all periods while operating income and EPS-TTM of -1.81 are negative, and what reconciles these figures?
• What is the basis for the forward P/E of 33 given the negative trailing EPS, and what earnings trajectory does it assume?
• What are the 13F institutional holder positions and SEC Form 4 insider transactions underlying the pillar scores, given that the holders section is empty?